

The prescription of anthracyclines during pregnancy in haematology: case reports and literature review

C. Peloso¹, M.-T. Baylatry¹, E. Elefant², F. Isnard³, C. Fernandez¹, A.-C. Joly¹

¹Saint-Antoine Hospital, Pharmacy, ²Trousseau Hospital, CRAT, ³Saint-Antoine Hospital, Haematology, APHP, Paris, France

Introduction

- Anthracyclines is one of the most important group of drugs used nowadays in cancer chemotherapy.
- Chemotherapy is essential in the management of haematological malignancies.
- When acute leukemia (AL), aggressive non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) occurs during pregnancy, chemotherapy is an emergency but fetal risk must be considered.
- >> Our objective is to evaluate fetal and maternal outcomes associated with anthracyclines prescriptions in pregnant women with haematological malignancies.

Materials and Methods

- Literature review was performed in Pudmed and Embase databases until May 2012
- keywords: pregnancy, acute leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, cancer chemotherapy, doxorubicin, daunorubicin and idarubicin
- selection criteria of articles: diagnosis of haematological malignancy and anthracycline prescription during pregnancy, fetal outcome
- Cases of pregnant women with AL, NHL or HL treated by anthracyclines were collected from Teratogenic Agent Information Centre (CRAT), a French reference centre providing specialized information for clinicians about drug use in pregnancy.

Results

Literature review: 81 articles


134 cases of pregnant women with haematological malignancies

Maternal outcomes

n=37


unknown

treated by anthracyclines during pregnancy



Case reports from CRAT

5 cases of pregnant women with haematological malignancies treated by anthracyclines



- chemotherapy in early 3rd trimester
- doxorubicin or daunorubicin at standard dosage
- 5 normal newborns (but 2 preterms)
- 3 maternal complete remission (2 unknown maternal outcomes)



Embryo-fetal toxicity depends on gestational age, anthracycline and haematological malignancy.

▶ 2nd or 3rd trimester exposures were mainly associated with favorable neonatal outcomes.

Idarubicin was specifically associated with risk of fetal cardiotoxicity, probably due to its lipophily, facilitating placental transfer.

• Unfavorable fetal outcomes more frequent in AL compared to lymphomas (NHL, HL), probably reflect that chemotherapy can never be delayed post partum in AL.

> Anthracyclines prescription for haematological malignancies is possible in 2nd and 3rd trimesters of pregnancy with minimal risk to the developing fetus and then must be conducted by a multidisciplinary team.